HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients
HBsAg Loss Adding Pegylated Interferon Alfa-2a in HBeAg-negative Patients Treated With Nucleos(t)Ide Analogues.
Lead SponsorHepa C
StatusCompleted No Results Posted
Indication/ConditionChronic Hepatitis B (HBeAg-negative)
Intervention/Treatmentinterferon alpha-2b ...
Chronic hepatitis B (CHB) affects more than 350 million people worldwide. The most common form in Europe is CHB HBeAg-negative. Antiviral treatment of CHB HBeAg-negative patients includes chronic administration of nucleos(t)ide analogues (NUC) or pegylated interferon (PegIFN) during 12 months. Typically, PegIFN allows immune control of CHB and antigen "s" (HBsAg) loss in around 4% of patients compared to less than 0,1% using NUC. Recently, it has been described that HBsAg quantification (HBsAg-q) is useful to identify patients with high probability to lose HBsAg during follow-up. In addition, a proof-of-concept study with nine HBeAg-negative patients receiving NUC showed that adding PegIFN (16 weeks) achieved HBsAg loss in one patient (11%). The aim of our study is to evaluate the efficacy and safety adding PegIFN (48 weeks) in treated HBeAg-negative patients with NUC.
adding Pegylated interferon alfa-2a (180 microgs /week during 48 weeks) in HBeAg-negative patients receiving nucleos(t)ide analogues
HBeAg-negative patients receiving nucleos(t)ide analogues
Inclusion Criteria: Chronic hepatitis B (HBeAg-negative) Signed inform consent Aged > 18 Exclusion Criteria: Contraindications for Pegylated interferon (cirrhosis, pregnancy, others) Previous treatment with interferon or Pegylated interferon Previous HBsAg loss Treatment duration with Nucleos(t)ide analogues less than 2 years Poor adherence to Nucleos(t)ide analogues